MedPath

福安药业集团宁波天衡制药有限公司

Ownership
-
Established
1992-08-12
Employees
-
Market Cap
-
Website
http://fapharm.com/thzy/

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

121

NMPA:121

Drug Approvals

Rebamipide Tablets

Product Name
瑞巴派特片
Approval Number
国药准字H20249201
Approval Date
Oct 29, 2024
NMPA

Sulindac

Product Name
舒林酸
Approval Number
国药准字H20055039
Approval Date
Sep 20, 2024
NMPA

Carvedilol

Product Name
卡维地洛
Approval Number
国药准字H20000099
Approval Date
Sep 20, 2024
NMPA

ETIMICIN SULFATE AND SODIUM CHLORIDE INJECTION

Product Name
硫酸依替米星氯化钠注射液
Approval Number
国药准字H20051631
Approval Date
Aug 7, 2024
NMPA

Iohexol Injection

Product Name
枢刻明
Approval Number
国药准字H20083568
Approval Date
Jul 16, 2024
NMPA

BACLOFEN TABLETS

Product Name
枢芬
Approval Number
国药准字H19980103
Approval Date
Jul 16, 2024
NMPA

Glibenclamide Tablets

Product Name
格列本脲片
Approval Number
国药准字H33021899
Approval Date
Jul 15, 2024
NMPA

CARVEDILOL TABLETS

Product Name
枢衡
Approval Number
国药准字H20052428
Approval Date
Jul 15, 2024
NMPA

Etimicin Sulfate and Sodium Chloride Injection

Product Name
硫酸依替米星氯化钠注射液
Approval Number
国药准字H20051632
Approval Date
Jul 15, 2024
NMPA

Tropisetron Hydrochloride Injection

Product Name
盐酸托烷司琼注射液
Approval Number
国药准字H20193124
Approval Date
Mar 8, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 13
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.